Quantcast

Latest placebo Stories

2014-08-14 23:01:06

New Onnit T+ Formula Increases Strength 36% Over Placebo In FSU Clinical Trial AUSTIN, TX (PRWEB) August 14, 2014 A groundbreaking clinical trial for strength based athletes has just been presented at this year’s National Strength and Conditioning Association (NSCA) annual conference. Dr. Michael Ormsbee, a professor of human sciences at Florida State University, led a team of investigators to analyze a 4-week supplementation regimen of Onnit’s T+ on college-aged powerlifters. T+ is...

2014-08-05 23:06:47

JDS Therapeutics Announces U.S. Launch of Physician Recommended Relizen®, a Safe, Natural Therapy for Hot Flashes Los Angeles (PRWEB) August 05, 2014 Relizen®†, a patented, non-hormonal nutritional supplement for the relief of hot flashes associated with menopause, is now available to U.S. consumers for purchase at Relizen.com. Over 43 million women are of menopausal age in the United States. Seventy-five percent of women report experiencing hot flashes, and 87 percent of...

2014-07-29 08:33:38

NEW YORK, July 29, 2014 /PRNewswire/ -- Recently unveiled at the annual American Society of Clinical Psychopharmacology conference in Hollywood, FL, a new randomized, double-blinded, placebo-controlled human clinical trial conducted by The Brain Institute, at the University of Utah, found that adolescent males experienced increased motor speed and attention after supplementation of citicoline. The trial involved 75 adolescent males over a 28-day period in which the citicoline, a known...

2014-07-25 10:45:39

The Lancet Paracetamol is no better than placebo at speeding recovery from acute episodes of lower back pain or improving pain levels, function, sleep, or quality of life, according to the first large randomised trial to compare the effectiveness of paracetamol with placebo for low-back pain. The findings, published in The Lancet, question the universal endorsement of paracetamol as the first choice painkiller for low-back pain, say the authors. Low-back pain is the leading cause of...

2014-07-21 10:19:04

North Shore-Long Island Jewish (LIJ) Health System The brain network measures placebo effects in Parkinson's disease patients Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation. Parkinson's disease is the second most common neurodegenerative disease in the...

2014-07-17 16:26:33

MELBOURNE, Australia, July 17, 2014 /PRNewswire/ -- Prana Biotechnology (NASDAQ: PRAN; ASX: PBT) has today provided an update on its clinical development program for Alzheimer's disease. Professor Colin Masters, the Florey Institute of Neuroscience and Mental Health, The University of Melbourne, will today include data from Prana's Phase 2 IMAGINE and EURO trials in his presentation at the Alzheimer's Association International Conference in Copenhagen, Denmark. The presentation is...

2014-07-10 08:29:02

OSAKA, Japan and DURHAM, N.C., July 10, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), will present data during multiple poster and oral sessions at the upcoming Alzheimer's Association International Conference(®) 2014 (AAIC(®)), taking place in Copenhagen, Denmark from July 12-17, 2014. "Studies show that individuals with mild cognitive impairment--a slight, although noticeable and measurable...

2014-07-09 16:28:56

- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1] EAST HANOVER, N.J., July 9, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published the results from two pivotal Phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab (AIN457). Secukinumab met all primary and key secondary...

2014-07-09 16:28:51

Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine TARRYTOWN, N.Y. and PARIS, July 9, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. All doses of dupilumab met the primary endpoint...

2014-07-07 08:27:32

- Pre-NDA meeting scheduled with FDA in July DUBLIN and RALEIGH, N.C., July 7, 2014 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. BEMA buprenorphine is being developed for the management of pain severe enough to require...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related